

RESEARCH ARTICLE

Obesity in children and adolescents and the risk of ovarian cancer: A systematic review and dose–response meta-analysis

Nan Ding^{1,2‡}, Junyi Zhan^{1,3‡}, Youjin Shi^{1,2}, Tianci Qiao^{1,4}, Panpan Li^{1,2}, Tingting Zhang^{1,2*}

1 Shanghai University of Traditional Chinese Medicine, Shanghai, China, **2** Department of Gynecology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China, **3** Department of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China, **4** Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

‡ ND and JZ are contributed to the work equally and should be regarded as co-first authors.

* tingting185@aliyun.com



OPEN ACCESS

Citation: Ding N, Zhan J, Shi Y, Qiao T, Li P, Zhang T (2022) Obesity in children and adolescents and the risk of ovarian cancer: A systematic review and dose–response meta-analysis. *PLoS ONE* 17(12): e0278050. <https://doi.org/10.1371/journal.pone.0278050>

Editor: Alok Deoraj, Florida International University, UNITED STATES

Received: July 19, 2022

Accepted: November 8, 2022

Published: December 7, 2022

Copyright: © 2022 Ding et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its [Supporting Information](#) files.

Funding: This study is supported by grant shsicdzk04501 from Shanghai “13th Five-Year Plan” Key Clinical Specialty (Traditional Chinese Medicine Gynecology Department). The funders participated in the design of this study and the authors declare no conflict of interest.

Competing interests: The authors have declared that no competing interests exist.

Abstract

Objective

The relationship between obesity in children and adolescents and the risk of ovarian cancer remains controversial. The aim of this meta-analysis was to explore the exact shape of this relationship.

Methods

We conducted dose–response meta-analyses of cohort and case–control studies, including published studies derived from searches in the PubMed, Embase, Web of Science and Cochrane Library databases until October 2022. Pooled effect size estimates are expressed as relative risks (RRs) or odds ratios (ORs) with 95% confidence intervals (CIs) and were evaluated by fixed-effect models. A nonlinear dose–response meta-analysis was performed by using a restricted cubic spline model.

Results

After screening 4215 publications, 10 studies were included in the present meta-analysis. Overall analyses revealed statistically significant associations of obesity in children and adolescents with ovarian cancer (adjusted RR = 1.19, 95% CI: 1.11 to 1.28, $P < 0.001$). Moreover, the association was consistently significant in most subgroup analyses, for example, using geographic stratification, the results remained stable both in the Americas (RR = 1.11; 95% CI: 1.01 to 1.21; $P = 0.022$) and Europe (RR = 1.46; 95% CI: 1.21 to 1.77; $P < 0.001$). For the dose–response analyses, the risk of ovarian cancer increased with the degree of obesity, and the trend increased rapidly when body mass index (BMI) was over 25.95 kg/m².

Conclusion

Our findings indicate that obesity in children and adolescents is a risk factor for ovarian cancer, and the risk increases with increasing BMI.

Introduction

Ovarian cancer is the seventh most common cancer and the eighth leading cause of cancer death in women worldwide [1]. Due to the deficiency of effective methods for screening and atypical clinical symptoms in the early stage, the majority of ovarian cancer cases are usually diagnosed in the advanced stages [2, 3], and their 5-year survival rate is less than 50% [4]. Therefore, establishing primary prevention for ovarian cancer, although challenging, is a crucial part of public health.

Over the past decades, much evidence has indicated that adult obesity is an essential factor in the development of ovarian cancer [5–9], whereas little is known about the association between obesity in childhood and adolescence and ovarian cancer. Given the long latency of cancer development, the accumulation of risk factors over time from childhood and adolescence may be more closely associated with ovarian cancer than in adulthood [10]. From 1975 to 2016, the global prevalence of overweight or obesity among female children and adolescents aged 5–19 years increased by eight times [11] and showed a continuously increasing trend [12]. A meta-analysis showed that obese children and adolescents were approximately five times more likely to be obese in adulthood than those who were not obese [13], which suggests that childhood and adolescence may be a critical window of ovarian carcinogenic susceptibility to obesity [14, 15]. However, the current findings of the association between obesity in childhood and adolescence and ovarian cancer are mixed. Some observational studies have shown that obesity in adolescence has a stronger association with ovarian cancer than that in adulthood [16, 17]. Other studies have reported the opposite that there is no significant association between obesity and ovarian cancer at age 18 [18, 19]. Thus, it is essential to verify the association between obesity in children and adolescents and ovarian cancer.

To provide more convincing epidemiological evidence for further studies, we performed this meta-analysis to better evaluate the association between obesity in children and adolescents and ovarian cancer and to analyze whether there is a dose–response. Furthermore, a considerable number of predesignated subgroup analyses were carried out to identify covariates that may influence the pooled effect size estimates and test the stability of the results.

Methods

Guidelines and ethics

The reports in the study conformed to the guidelines in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [20]. The PRISMA checklist is presented in [S1 Table](#). The study protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO), and the registration number is CRD42022331501. Since the present meta-analysis was based on published research, the approval and informed consent steps of the Ethics Committee were omitted.

Search strategy

The literature search was conducted in the PubMed, Embase, Web of Science and Cochrane Library databases as of April 6, 2022, and was updated on October 5, 2022. The full search

strategy is presented in the [S2 Table](#). In addition, we manually searched the reference lists of the main references to avoid potential omissions. The included articles were not subject to language and publication restrictions. If necessary, we contacted the author to try to obtain more relevant information.

The search process was independently performed by two investigators (N.D. and J.Z.) using the same medical subject terms. All retrieved references were combined and duplicates were removed.

Eligibility criteria

This meta-analysis included articles that met the following criteria: (i) Study participants: aged less than 19 years; (ii) Endpoints: all types of ovarian cancer; (iii) Study design: cohort studies or case-control studies; (iv) Exposure: overweight or obesity in children or adolescents; (v) Relative risk (RR), hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (95% CI) was used to measure the degree of relationship between child and adolescent obesity and ovarian cancer.

Articles were excluded if they were case reports, case series, editorials, or narrative reviews, or if the participants belonged to a population with a specific disease. Articles where the full-text was not available or those not written in the English language were also excluded. Furthermore, when multiple studies were from the same cohort, we included only those with the longest follow-up period and the largest sample size.

Data abstraction and quality assessment

We extracted the following data from each eligible study: (i) Characteristic information: first author, time of publication, country or region, study design, study period, follow-up year, baseline age, outcome, sample size, and number of cases. (ii) Exposure evaluation: BMI or weight, or other measures used to assess obesity. Moreover, the reference categories of the definition or classification were treated as the benchmark for extracting data. (iii) Effect size estimate: adjusted RRs, HRs or ORs with 95% CIs by categories.

In addition, we recorded the adjustment of covariates in each study in detail for subgroup analysis, such as age, duration of oral contraceptive use, age at menarche, menopausal status, family history, race, parity, and tubal ligation history.

Data were extracted independently from each included study by two investigators (N.D. and J.Z.). The divergence was resolved by the co-evaluation of original articles or by a third author if necessary (Y.S.).

The quality of all included studies was assessed by the Newcastle-Ottawa Scale (NOS) for cohort and case-control studies [21]. The evaluation of a study using the NOS is based on the following aspects: the selection and comparability of study groups, and the assessment of exposures and outcomes.

Statistical analyses

Data management and analysis were analyzed by STATA 14.1. The effect size was estimated as RR, HR or OR with a 95% CI. We converted HRs into RRs and used ORs as approximations of RRs to combine effect values [22, 23]. The meta-regression analysis model was selected according to the results of the between-test heterogeneity. When the heterogeneity was significant, a random effect model was selected, and a fixed effect model was derived when the heterogeneity was not significant [24]. The Cochrane Q test and inconsistency index (I^2) were used to quantify the heterogeneity between studies. For the Cochrane Q test, $p < 0.1$ was considered statistically significant, and for the I^2 statistic, I^2 values greater than 50% were considered to indicate

significant heterogeneity. Since there was no significant heterogeneity between studies, we derived pooled effect size estimates under the fixed model.

The generalized least squares regression proposed by Greenland and Longnecker was used to establish the dose–response relationship. The median of each category of BMI was regarded as the exposure dose, and the length of the adjacent interval was treated as the length of the open interval. The restricted cubic splines of exposure distributions with three knots fixed at the 25th, 50th, and 75th percentiles were used to test nonlinearity between obesity in children and adolescents and ovarian cancer.

To identify the factors that may affect the pooled effect size estimates and test the stability of the results, a considerable number of predesignated subgroup analyses were performed based on demographic characteristics, research characteristics, and whether the covariates were adjusted. A sensitivity analysis was used to assess the impact of each article on the overall stability.

The risk of publication bias was evaluated by Begg's funnel plots and Egger regression asymmetry tests. The number of theoretically missing studies was estimated by the trim-and-fill method.

Results

Eligible studies

A total of 4215 publications were initially identified by searching the medical subject words in the previously mentioned public databases, and 10 articles were selected [14, 16, 17, 25–31], including 588,134 participants. The results of some articles were reported by different age groups and these were listed and treated separately. The detailed search strategy, inclusion process, and exclusion process are presented in Fig 1.

Study characteristics

The baseline characteristics of the 10 eligible articles including 5 cohort studies [14, 16, 17, 25, 28] and 5 case–control studies [26, 27, 29–31], are presented in Table 1. The original data used to reach the conclusions were recorded on S3 Table to improve the repeatability of the present study. Depending on the measurements of body size, all studies reported BMI in children and adolescents, and 4 studies reported weight [26, 29–31]. According to age, 8 articles reported BMI at 18 years of age [16, 17, 26–31], 1 article reported BMI at 17 years of age [25], and 2 articles reported BMI at 10 years of age [14, 16]. Based on geographical location, 7 articles were from the Americas [16, 17, 26, 28–31], 2 articles were from Europe [14, 25] and 1 article was from Asia [27]. Meanwhile, we made a detailed classification of adjusted multiple covariates.

Quality assessment

S4 and S5 Tables present the quality assessment of all eligible articles by using the NOS for cohort studies and case–control studies. The average scores were 8 (range: 7 to 9) and 7 (range: 6 to 8) respectively, with a standard deviation of 0.71.

Meta-analyses

After summarizing the results of all qualified studies, we speculated that obesity in children and adolescents was statistically associated with an increased risk of ovarian cancer (RR = 1.19, 95% CI: 1.11 to 1.28, $P < 0.001$). The estimated results displayed in Fig 2 addressed the association of obesity in children and adolescents with ovarian cancer.




Fig 1. Flow chart of study selection in this meta-analysis.

<https://doi.org/10.1371/journal.pone.0278050.g001>

A series of subgroup analyses were conducted to reveal the potential factors that may affect the pooled effect size estimates and test the stability of the results. The detailed overall and subgroup analyses are shown in [Table 2](#). By study design, the association between obesity in children and adolescents and ovarian cancer was statistically significant in both cohort studies (RR = 1.29, 95% CI: 1.13 to 1.47, $P < 0.001$) and case-control studies (OR = 1.15, 95% CI: 1.06 to 1.25, $P = 0.001$). By baseline age, the association of obesity in children and adolescents and ovarian cancer was significant at 18 years of age (RR = 1.15; 95% CI: 1.07 to 1.24; $P = 0.001$), while there was no significant association at 10 years of age (RR = 1.07; 95% CI: 0.95 to 1.20; $P = 0.254$). However, the pooled result at 10 years of age should be considered with caution due to the limited number of included studies ($n = 2$). By exposure assessment, the significant association between obesity in children and adolescents and ovarian cancer was consistent both for researchers' assessment (RR = 1.46; 95% CI: 1.21 to 1.77; $P < 0.001$) and self-report (RR = 1.15; 95% CI: 1.07 to 1.24; $P = 0.001$). By geographic region, ovarian cancer risk was significantly associated with obesity in children and adolescents in all subgroups (America: RR = 1.11; 95% CI: 1.01 to 1.21; $P = 0.022$, Europe: RR = 1.46; 95% CI: 1.21 to 1.77; $P < 0.001$).

Table 1. Descriptive characteristics of studies on the association of obesity in children and adolescents with ovarian cancer.

First author	Year	Country	Study Design	Study period	Follow-up (years)	Exposure assessment	Age exposure assessed	Outcome	Adjusted variables
Kuper, H.	2002	US	C-C	1992–1997	NA	BMI, weight	18	Epithelial ovarian cancer	age, site, parity, oral contraceptive use, family history of breast, ovarian, or prostate cancer in a first-degree relative, tubal ligation, education, and marital status
Lubin, F.	2003	Israel	C-C	1994–1999	NA	BMI	18	Epithelial ovarian cancer	family history of either breast or ovarian cancer in first-degree family members, use of oral contraceptive, parity, menopausal status, age at menarche, infertility problems requiring treatment, change in body mass index
Engeland, A.	2003	Norway	Cohort	1963–1999	31.6	BMI	14–16, 17–19	ovarian cancer	age at measurement and birth cohort
Anderson, J. P.	2004	US	Cohort	1986–2000	15	BMI	18	Epithelial ovarian cancer	age, family history of ovarian cancer, hysterectomy status, oophorectomy status, number of live births, pack-years of smoking, and estrogen replacement therapy (ever/ never)
Hoyo, C.	2005	US	C-C	1999–2003	NA	BMI, weight	18	Epithelial ovarian cancer	race, age, parity, ovarian cancer history, breast cancer history, hysterectomy, oral contraceptive use, and menstrual status
Greer, J. B.	2006	US	C-C	1994–1998	NA	BMI, weight	18	Epithelial ovarian cancer	age, race (white/other), number of live births, family history of ovarian cancer, tubal ligation, and oral contraceptive use (ever/never)
Rossing, M. A.	2006	US	C-C	1994–1998	NA	BMI, weight	18	Epithelial ovarian cancer	age, race, study site, number full-term births and duration of oral contraceptive use
Leitzmann, M. F.	2009	US	Cohort	1996–2003	7	BMI	18	Epithelial ovarian cancer	age, race/ethnicity, family history of breast or ovarian cancer, duration of oral contraceptive use, menopausal hormone therapy, and physical activity
Aarestrup, J.	2019	Denmark	Cohort	1978–2014	37	BMI	7, 8, 9, 10, 11, 12, 13	Epithelial ovarian cancer	birth weight
Huang, T.	2019	US	Cohort	1980–2012 1989–2013	32, 24	BMI	10, 18	ovarian cancer	age at menarche, tubal ligation, duration of oral contraceptive use, duration of premenopause, menopausal status, type of menopause, duration of estrogen-only hormone therapy use, duration of estrogen and progesterone hormone therapy use, duration of other hormone therapy use, height, parity and smoking status

C-C: case-control study; BMI: body mass index

<https://doi.org/10.1371/journal.pone.0278050.t001>

By body size evaluation methods, in addition to BMI, excessive weight also showed a significant correlation with ovarian cancer (OR = 1.14; 95% CI: 1.04 to 1.25; P = 0.004). To explore important covariates that may affect the association between obesity in children and adolescents and ovarian cancer risk, we further pooled the estimated effect sizes of all studies that adjusted the same covariable. The results indicate that the association remained significantly positive in most subgroups after adjusting for covariables, including age, race, duration of oral contraceptive use, age at menarche, menopausal status, family history, and parity. These results suggested that obesity in children and adolescents was an independent risk factor for ovarian cancer.

A sensitivity analysis was conducted by omitting each article sequentially to further confirm the stability of the results, which revealed that none of these studies had a significant impact on the pooled estimate effect size (S1 Fig).




Fig 2. Association of obesity in children and adolescents with ovarian cancer in studies providing relative risks (RRs) and 95% confidence intervals (CIs).

<https://doi.org/10.1371/journal.pone.0278050.g002>

Dose–response analyses

The estimated effect sizes of ovarian cancer risk by BMI or weight category are presented in [S6 Table](#), indicating that both BMI and weight show a higher risk of ovarian cancer with a higher level of adiposity. The dose–response relationship between BMI in children and adolescents and ovarian cancer is illustrated in [Fig 3](#) and shows a J-distribution, indicating that the ovarian cancer risk would increase rapidly when BMI is greater than 25.95 kg/m².

Publication bias

Begg's and filled funnel plots were used to assess publication bias for the association of obesity in children and adolescents with ovarian cancer and are presented in [S2 Fig](#). There was no asymmetry evidence of study effects in Begg's test and further Egger's tests confirmed that ($P = 0.650$). The filled funnel plots revealed 3 missing items in the theory study.

Discussion

To the best of our knowledge, this meta-analysis is the first assessment exploring the association between obesity in children and adolescents and ovarian cancer. Ten eligible studies with

Table 2. Overall and subgroup analyses of the association of obesity in children and adolescents with ovarian cancer risk.

Groups	Number of qualified studies	Effect size	95% CI	p	I ²
Overall analyses					
Risk of ovarian cancer	10	1.19	1.11–1.28	<0.001	18.80%
Subgroup analyses					
Study design					
Cohort	5	1.29	1.13–1.47	<0.001	4.30%
C-C	5	1.15	1.06–1.25	0.001	21.90%
Measurement of body size					
BMI	10	1.19	1.11–1.28	<0.001	18.80%
Weight	4	1.14	1.04–1.25	0.004	0.00%
Baseline age					
18	8	1.15	1.07–1.24	0.001	12.70%
17	1	1.49	1.14–1.94	-	-
10	2	1.07	0.95–1.20	0.254	19.40%
Geographic region					
America	7	1.11	1.01–1.21	0.022	2.90%
Europe	2	1.46	1.21–1.77	<0.001	0.00%
Asia	1	1.30	1.11–1.53	-	-
Exposure assessment					
Self-reported	8	1.15	1.07–1.24	0.001	12.70%
By researchers	2	1.46	1.21–1.77	<0.001	0.00%
Adjusted for covariates					
age	8	1.19	1.10–1.29	<0.001	17.40%
Duration of oral contraceptive use	7	1.15	1.06–1.24	0.001	14.60%
Age at menarche	2	1.22	1.07–1.39	0.003	27.40%
Menopausal status	3	1.17	1.05–1.30	0.004	6.60%
Family history	5	1.17	1.07–1.28	0.001	28.20%
Parity	7	1.14	1.06–1.24	0.001	15.70%
Tubal ligation history	3	1.06	0.95–1.19	0.283	18.00%
Smoking	2	1.11	0.90–1.38	0.334	10.50%
Race	3	1.12	1.00–1.26	0.048	0.00%

C-C: case-control study; BMI: body mass index.

<https://doi.org/10.1371/journal.pone.0278050.t002>

more than 500,000 participants were included in this meta-analysis. Our key findings are that children and adolescents with obesity had a 1.19 times higher risk of ovarian cancer than those without obesity. When considering the adjustment of covariables, the association was consistently significant in most subgroups, suggesting that the associations were independent of these risk factors. Moreover, the J-distribution dose-response in the relationship between BMI in children and adolescents and ovarian cancer indicates that ovarian cancer risk increases with more serious obesity in children and adolescents. Our findings suggest that it is necessary to pay more attention to the control of obesity in children and adolescents to prevent ovarian cancer.

In previous literature, some prospective cohort studies had similar conclusions that obesity in children and adolescents could be a risk factor for ovarian cancer [14, 25]. However, several observational studies have shown controversial findings. A case-control study including 1988 participants in the United States found that there was no statistical association between obesity




Fig 3. The dose–response plot for the association of obesity in children and adolescents with ovarian cancer.

<https://doi.org/10.1371/journal.pone.0278050.g003>

at the age of 18 as measured by BMI and ovarian cancer (adjusted OR = 1.7; 95% CI: 0.8 to 3.5). However, this association was significant relative to low weight compared with high weight at the age of 18 (adjusted OR = 1.5; 95% CI: 1.0 to 2.2) [31]. Similarly, Fairfield advocated that there was no statistically significant association between overweight at the age of 18 and ovarian cancer (adjusted RR = 1.12; 95% CI: 0.77 to 1.63) through the analysis of 109,445 participants in the Nurses' Health Study [18]. Recently, a meta-analysis from Byun and colleagues suggested that the risk of ovarian cancer increased each 15% when early-life BMI increases every 5 kg/m², (RR = 1.15; 95% CI: 1.07 to 1.23), which provided high-level evidence that early-life obesity could be a significant risk factor for ovarian cancer [32]. Nevertheless, the number of included studies (6 cohort studies) was insufficient, and the data were mixed with the early adulthood results (age ≤ 25 years). Therefore, the association between obesity in children and adolescents and ovarian cancer could not be accurately interpreted.

To fill the research gap, the age of participants was restricted to less than 19 years old to focus on the association between obesity in children and adolescents and ovarian cancer. For the selection of literature, cohort studies and case–control studies were included to expand the sample size and diminish random error and selection bias. For the combination of estimated effect sizes, using multifactor adjusted effect values may better reduce the influence of covariates on the results. For the subgroup analyses, detailed classification was performed to expose potential factors that might affect the conclusions and test the stability of the results.

Furthermore, the dose–response analysis described the association between BMI in children and adolescents and ovarian cancer risk.

Our study provided evidence to support the long-term effects of obesity in children and adolescents associated with the risk of ovarian cancer. The pooled estimate effect sizes of both cohort studies and case–control studies showed statistically significant associations. The dose–response findings further confirmed our conclusion, that ovarian cancer risk increases with increasing BMI in children and adolescents, and ovarian cancer risk rapidly increases when BMI exceeds 25.95 kg/m². It is worth noting that, participants in late adolescence at the ages of 17 (RR = 1.49; 95% CI: 1.14 to 1.94) and 18 (RR = 1.15; 95% CI: 1.07 to 1.24) showed significant associations between obesity and ovarian cancer when stratified by age. However, there was no association at the age of 10 (RR = 1.07; 95% CI: 0.95 to 1.20). BMI at the age 10 was the result of body size estimation, which may cause information bias.

Until now, the biological mechanisms of increased ovarian cancer risk with obesity in children and adolescents have not been fully elucidated. Weight and BMI gain among children and adolescents may reflect prolonged exposure to obesity and continuous accumulation of risk factors throughout the life course, thus making children and adolescents more prone to the carcinogenic process. Obesity is a pathological state accompanied by overgrowth of adipose tissue. Adipocytes, the major component of adipose tissue, are involved in almost all ovarian cancer processes by secreting adipokines, metabolic remodeling and regulating the immune microenvironment, which can promote the growth, invasion, metastasis and angiogenesis of ovarian cancer [33]. On the one hand, adipocytes provide ovarian cancer with high-energy metabolites through altered lipid metabolism and resistance to mitochondrial apoptosis, which is one of the primordial drivers of cancer cell growth and proliferation [34, 35]. On the other hand, the immune microenvironment is considered a major factor in the development and progression of ovarian cancer. During weight gain, adipocytes contribute to the release of inflammatory factors such as tumor necrosis factor- α , interleukin (IL)-6 and IL-1 β from adipose tissue macrophages via paracrine pathways, inducing a chronic low-grade inflammatory microenvironment that stimulates persistent abnormal proliferation of ovarian epithelial cells [36, 37]. In addition, adipocytes can inhibit the antitumor activity of immune cells by expressing programmed death-ligand 1, allowing cancer cells to evade immune surveillance [38]. In obese populations, the excessive accumulation of adipocytes exerts a chronic and persistent effect on the immune microenvironment, which may lead to a higher risk of cancer in children and adolescents exposed to long-term persistent obesity than in adults. Meanwhile, obesity is associated with higher levels of androgens [39], and ovarian cancer preferentially develops in an androgen-rich hormonal environment [40]. Excess androgens may directly affect ovarian cancer development through androgen receptor signaling [41]. Puberty is accompanied by increased androgen secretion, and total testosterone levels are significantly higher in obese girls during puberty than in normal weight girls, which may further increase the risk of ovarian cancer [42, 43]. This biological change is consistent with our conclusion that there is a statistically significant association between obesity in puberty and ovarian cancer risk. From another point of view, the incessant ovulation hypothesis suggests that repeated ovarian epithelial damage and repair due to constant ovulation is an important risk factor for ovarian cancer, and therefore women with a high lifetime number of ovulatory cycles are at higher risk of ovarian cancer [44, 45]. Excessive body fat may lead to earlier puberty in girls [46] and contribute to increasing the lifetime number of ovulatory cycles, which may also be critical to the risk of ovarian cancer [15, 47]. Under the background of long-term follow-up, anthropometric data for children and adolescents are difficult to obtain, which hinders research on relevant biological mechanisms. In the future, further large and well-designed observational studies are needed to validate current theories.

There are also some limitations in this study that need to be addressed. First, our findings suggest that obesity in children and adolescents increases the risk of ovarian cancer. However, due to the lack of relevant literature containing childhood obesity data, the analysis of dose–response relationships by multiple age groups could not be performed. Therefore, more measurements across different age groups are needed to prove our results. Second, subgroup analyses indicated that most studies were performed in the Americas, which may be related to higher obesity rates in children and adolescents in the Americas [48], implying that the universality and difference of this association cannot be reasonably explained across multiple ethnic backgrounds. Third, there was no correction applied for adult obesity in this meta-analysis, because the original data from the included articles did not adjust for this factor.

Conclusion

Our dose–response meta-analysis supports that obesity in children and adolescents may independently increase the risk of ovarian cancer and that the degree of risk increases with the severity of obesity. However, the relationship with obesity in childhood is not clear. Future research through more large-scale, well-designed cohort studies on the relationship between childhood obesity and ovarian cancer is needed.

Supporting information

S1 Table. PRISMA checklist for systematic review.

(DOCX)

S2 Table. Search strategies for databases.

(DOCX)

S3 Table. Original data extracted from included studies.

(DOCX)

S4 Table. Newcastle–Ottawa scale for assessment of quality of cohort studies.

(DOCX)

S5 Table. Newcastle–Ottawa scale for assessment of quality of case–control studies.

(DOCX)

S6 Table. Estimate effect sizes of ovarian cancer risks by BMI or weight category.

(DOCX)

S1 Fig. Sensitivity analysis.

(DOCX)

S2 Fig. Begg’s and filled funnel plots for the association of obesity in children and adolescents with ovarian cancer.

(DOCX)

Author Contributions

Conceptualization: Nan Ding, Tingting Zhang.

Data curation: Nan Ding, Junyi Zhan, Youjin Shi.

Formal analysis: Junyi Zhan.

Methodology: Nan Ding, Junyi Zhan.

Supervision: Panpan Li.

Writing – original draft: Nan Ding, Junyi Zhan.

Writing – review & editing: Tianci Qiao.

References

1. Zhao L, Liang X, Wang L, Zhang X. The Role of miRNA in Ovarian Cancer: an Overview. *Reprod Sci*. 2022 Oct; 29(10):2760–2767. <https://doi.org/10.1007/s43032-021-00717-w> Epub 2022 Jan 1. PMID: 34973152; PMCID: PMC9537199.
2. Wentzensen N. Large ovarian cancer screening trial shows modest mortality reduction, but does not justify population-based ovarian cancer screening. *Evid Based Med*. 2016 Aug; 21(4):159. <https://doi.org/10.1136/ebmed-2016-110411> Epub 2016 Jul 22. PMID: 27450366.
3. Holmes D. Ovarian cancer: beyond resistance. *Nature*. 2015 Nov 26; 527(7579):S217. <https://doi.org/10.1038/527S217a> PMID: 26605761.
4. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin*. 2018 Jul; 68(4):284–296. <https://doi.org/10.3322/caac.21456> Epub 2018 May 29. PMID: 29809280; PMCID: PMC6621554.
5. Liu Z, Zhang TT, Zhao JJ, Qi SF, Du P, Liu DW, et al. The association between overweight, obesity and ovarian cancer: a meta-analysis. *Jpn J Clin Oncol*. 2015 Dec; 45(12):1107–15. <https://doi.org/10.1093/jjco/hyv150> Epub 2015 Oct 21. PMID: 26491203.
6. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. *PLoS Med*. 2012; 9(4):e1001200. <https://doi.org/10.1371/journal.pmed.1001200> Epub 2012 Apr 3. PMID: 22606070; PMCID: PMC3317899.
7. Aune D, Navarro Rosenblatt DA, Chan DS, Abar L, Vingeliene S, Vieira AR, et al. Anthropometric factors and ovarian cancer risk: a systematic review and nonlinear dose-response meta-analysis of prospective studies. *Int J Cancer*. 2015 Apr 15; 136(8):1888–98. <https://doi.org/10.1002/ijc.29207> Epub 2014 Sep 24. PMID: 25250505.
8. Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolaheer F, Webb PM. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. *Eur J Cancer*. 2007 Mar; 43(4):690–709. <https://doi.org/10.1016/j.ejca.2006.11.010> Epub 2007 Jan 12. PMID: 17223544.
9. Tanha K, Mottaghi A, Nojomi M, Moradi M, Rajabzadeh R, Lotfi S, et al. Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses. *J Ovarian Res*. 2021 Nov 11; 14(1):153. <https://doi.org/10.1186/s13048-021-00911-z> PMID: 34758846; PMCID: PMC8582179.
10. Aarestrup J, Bjerregaard LG, Meyle KD, Pedersen DC, Gjørde LK, Jensen BW, et al. Birthweight, childhood overweight, height and growth and adult cancer risks: a review of studies using the Copenhagen School Health Records Register. *Int J Obes (Lond)*. 2020 Jul; 44(7):1546–1560. <https://doi.org/10.1038/s41366-020-0523-9> Epub 2020 Jan 23. PMID: 31974406.
11. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. *Lancet*. 2017 Dec 16; 390(10113):2627–2642. [https://doi.org/10.1016/S0140-6736\(17\)32129-3](https://doi.org/10.1016/S0140-6736(17)32129-3) Epub 2017 Oct 10. PMID: 29029897; PMCID: PMC5735219.
12. Lobstein T, Jackson-Leach R, Moodie ML, Hall KD, Gortmaker SL, Swinburn BA, et al. Child and adolescent obesity: part of a bigger picture. *Lancet*. 2015 Jun 20; 385(9986):2510–20. [https://doi.org/10.1016/S0140-6736\(14\)61746-3](https://doi.org/10.1016/S0140-6736(14)61746-3) Epub 2015 Feb 19. PMID: 25703114; PMCID: PMC4594797.
13. Simmonds M, Llewellyn A, Owen CG, Woolacott N. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. *Obes Rev*. 2016 Feb; 17(2):95–107. <https://doi.org/10.1111/obr.12334> Epub 2015 Dec 23. PMID: 26696565.
14. Aarestrup J, Trabert B, Ulrich LG, Wentzensen N, Sørensen TIA, Baker JL. Childhood Overweight, Tallness, and Growth Increase Risks of Ovarian Cancer. *Cancer Epidemiol Biomarkers Prev*. 2019 Jan; 28(1):183–188. <https://doi.org/10.1158/1055-9965.EPI-18-0024> Epub 2018 Sep 27. PMID: 30262600; PMCID: PMC6325003.
15. Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. *Int J Cancer*. 2013 Jun 15; 132(12):2894–900. <https://doi.org/10.1002/ijc.27952> Epub 2012 Dec 13. PMID: 23175139; PMCID: PMC3806278.

16. Huang T, Tworoger SS, Willett WC, Stampfer MJ, Rosner BA. Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer. *Ann Oncol*. 2019 Feb 1; 30(2):303–309. <https://doi.org/10.1093/annonc/mdy546> PMID: 30576422; PMCID: PMC6821311.
17. Leitzmann MF, Koebrick C, Danforth KN, Brinton LA, Moore SC, Hollenbeck AR, et al. Body mass index and risk of ovarian cancer. *Cancer*. 2009 Feb 15; 115(4):812–22. <https://doi.org/10.1002/cncr.24086> PMID: 19127552; PMCID: PMC3507338.
18. Fairfield KM, Willett WC, Rosner BA, Manson JE, Speizer FE, Hankinson SE. Obesity, weight gain, and ovarian cancer. *Obstet Gynecol*. 2002 Aug; 100(2):288–96. [https://doi.org/10.1016/s0029-7844\(02\)02053-7](https://doi.org/10.1016/s0029-7844(02)02053-7) PMID: 12151152.
19. Baer HJ, Hankinson SE, Tworoger SS. Body size in early life and risk of epithelial ovarian cancer: results from the Nurses' Health Studies. *Br J Cancer*. 2008 Dec 2; 99(11):1916–22. <https://doi.org/10.1038/sj.bjc.6604742> Epub 2008 Oct 28. PMID: 19034283; PMCID: PMC2600685.
20. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021 Mar 29; 372:n71. <https://doi.org/10.1136/bmj.n71> PMID: 33782057; PMCID: PMC8005924.
21. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000.
22. Shor E, Roelfs D, Vang ZM. The "Hispanic mortality paradox" revisited: Meta-analysis and meta-regression of life-course differentials in Latin American and Caribbean immigrants' mortality. *Soc Sci Med*. 2017 Aug; 186:20–33. <https://doi.org/10.1016/j.socscimed.2017.05.049> Epub 2017 May 26. PMID: 28577458.
23. VanderWeele TJ. On a Square-Root Transformation of the Odds Ratio for a Common Outcome. *Epidemiology*. 2017 Nov; 28(6):e58–e60. <https://doi.org/10.1097/EDE.0000000000000733> PMID: 28816709; PMCID: PMC5617805.
24. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. *Am J Epidemiol*. 1992 Jun 1; 135(11):1301–9. <https://doi.org/10.1093/oxfordjournals.aje.a116237> PMID: 1626547.
25. Engeland A, Tretli S, Bjørge T. Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. *J Natl Cancer Inst*. 2003 Aug 20; 95(16):1244–8. <https://doi.org/10.1093/jnci/djg010> PMID: 12928351.
26. Kuper H, Cramer DW, Titus-Ernstoff L. Risk of ovarian cancer in the United States in relation to anthropometric measures: does the association depend on menopausal status? *Cancer Causes Control*. 2002 Jun; 13(5):455–63. <https://doi.org/10.1023/a:1015751105039> PMID: 12146850.
27. Lubin F, Chetrit A, Freedman LS, Alfandary E, Fishler Y, Nitzan H, et al. Body mass index at age 18 years and during adult life and ovarian cancer risk. *Am J Epidemiol*. 2003 Jan 15; 157(2):113–20. <https://doi.org/10.1093/aje/kwf184> PMID: 12522018.
28. Anderson JP, Ross JA, Folsom AR. Anthropometric variables, physical activity, and incidence of ovarian cancer: The Iowa Women's Health Study. *Cancer*. 2004 Apr 1; 100(7):1515–21. <https://doi.org/10.1002/cncr.20146> PMID: 15042687.
29. Hoyo C, Berchuck A, Halabi S, Bentley RC, Moorman P, Calingaert B, et al. Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women. *Cancer Causes Control*. 2005 Oct; 16(8):955–63. <https://doi.org/10.1007/s10552-005-3205-y> PMID: 16132804.
30. Greer JB, Modugno F, Ness RB, Allen GO. Anthropometry and the risk of epithelial ovarian cancer. *Cancer*. 2006 May 15; 106(10):2247–57. <https://doi.org/10.1002/cncr.21830> PMID: 16596653.
31. Rossing MA, Tang MT, Flagg EW, Weiss LK, Wicklund KG, Weiss NS. Body size and risk of epithelial ovarian cancer (United States). *Cancer Causes Control*. 2006 Jun; 17(5):713–20. <https://doi.org/10.1007/s10552-006-0010-1> PMID: 16633919.
32. Byun D, Hong S, Ryu S, Nam Y, Jang H, Cho Y, et al. Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose-response meta-analysis of prospective studies. *Br J Cancer*. 2022 Mar; 126(4):664–672. <https://doi.org/10.1038/s41416-021-01625-1> Epub 2021 Nov 12. PMID: 34773099; PMCID: PMC8854408.
33. Dai L, Song K, Di W. Adipocytes: active facilitators in epithelial ovarian cancer progression? *J Ovarian Res*. 2020 Sep 23; 13(1):115. <https://doi.org/10.1186/s13048-020-00718-4> PMID: 32967712; PMCID: PMC7513299.
34. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. *Nat Med*. 2011 Oct 30; 17(11):1498–503. <https://doi.org/10.1038/nm.2492> PMID: 22037646; PMCID: PMC4157349.
35. Nowicka A, Marini FC, Solley TN, Elizondo PB, Zhang Y, Sharp HJ, et al. Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. *PLoS One*.

- 2013 Dec 2; 8(12):e81859. <https://doi.org/10.1371/journal.pone.0081859> PMID: 24312594; PMCID: PMC3847080.
36. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol*. 2011 Feb; 11(2):85–97. <https://doi.org/10.1038/nri2921> Epub 2011 Jan 21. PMID: 21252989; PMCID: PMC3518031.
 37. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. *Nature*. 2017 Feb 8; 542(7640):177–185. <https://doi.org/10.1038/nature21363> PMID: 28179656.
 38. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. *Ann Oncol*. 2016 Mar; 27(3):409–16. <https://doi.org/10.1093/annonc/mdv615> Epub 2015 Dec 17. PMID: 26681673.
 39. Pasquali R, Oriolo C. Obesity and Androgens in Women. *Front Horm Res*. 2019; 53:120–134. <https://doi.org/10.1159/000494908> Epub 2019 Sep 9. PMID: 31499497.
 40. Silva EG, Tornos C, Fritsche HA Jr, el-Naggar A, Gray K, Ordonez NG, et al. The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. *Mod Pathol*. 1997 Sep; 10(9):879–83. PMID: 9310950.
 41. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. *Cancer Epidemiol Biomarkers Prev*. 2005 Jan; 14(1):98–107. PMID: 15668482.
 42. McCartney CR, Blank SK, Prendergast KA, Chhabra S, Eagleson CA, Helm KD, et al. Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. *J Clin Endocrinol Metab*. 2007 Feb; 92(2):430–6. <https://doi.org/10.1210/jc.2006-2002> Epub 2006 Nov 21. PMID: 17118995; PMCID: PMC2196134.
 43. Chung WM, Chen L, Chang WC, Su SY, Hung YC, Ma WL. Androgen/Androgen Receptor Signaling in Ovarian Cancer: Molecular Regulation and Therapeutic Potentials. *Int J Mol Sci*. 2021 Jul 20; 22(14):7748. <https://doi.org/10.3390/ijms22147748> PMID: 34299364; PMCID: PMC8304547.
 44. Fathalla MF. Incessant ovulation—a factor in ovarian neoplasia? *Lancet*. 1971 Jul 17; 2(7716):163. [https://doi.org/10.1016/s0140-6736\(71\)92335-x](https://doi.org/10.1016/s0140-6736(71)92335-x) PMID: 4104488.
 45. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. "Incessant ovulation" and ovarian cancer. *Lancet*. 1979 Jul 28; 2(8135):170–3. [https://doi.org/10.1016/s0140-6736\(79\)91435-1](https://doi.org/10.1016/s0140-6736(79)91435-1) PMID: 89281.
 46. Aksglaede L, Juul A, Olsen LW, Sørensen TI. Age at puberty and the emerging obesity epidemic. *PLoS One*. 2009 Dec 24; 4(12):e8450. <https://doi.org/10.1371/journal.pone.0008450> PMID: 20041184; PMCID: PMC2793517.
 47. Yang HP, Murphy KR, Pfeiffer RM, George N, Garcia-Closas M, Lissowska J, et al. Lifetime Number of Ovulatory Cycles and Risks of Ovarian and Endometrial Cancer Among Postmenopausal Women. *Am J Epidemiol*. 2016 May 1; 183(9):800–14. <https://doi.org/10.1093/aje/kwv308> Epub 2016 Apr 15. PMID: 27190045; PMCID: PMC4851993.
 48. Janssen I, Katzmarzyk PT, Boyce WF, Vereecken C, Mulvihill C, Roberts C, et al. Comparison of overweight and obesity prevalence in school-aged youth from 34 countries and their relationships with physical activity and dietary patterns. *Obes Rev*. 2005 May; 6(2):123–32. <https://doi.org/10.1111/j.1467-789X.2005.00176.x> PMID: 15836463.